Last week was a rough one for Devon Energy's (NYSE: DVN) investors. First off, shares of the shale giant tumbled double-digits after the company reported fourth-quarter results that were well below expectations due to production problems entirely out of its control. On top of that, the oil giant didn't join most peers in announcing an increase in cash heading back to investors through a higher dividend or a share-repurchase program. However, one thing CEO Dave Hager made clear on the accompanying conference call was that the company planned to send more cash to investors in the future. Here's a look at why Devon wants investors to wait a little while longer. Growing something great takes time. Image source: Getty Images. Addressing the elephant in the room Hager led off his prepared comments on the call stating: I want to address a topic that we have received a lot of questions on, and that is, why we have not authorized a share-repurchase program. Let me be clear, as we … [Read more...] about Why This Oil Stock Wants Investors to Be Patient
I wrote in November 2017 that I thought Novavax (NASDAQ: NVAX) stock could double by the end of 2018. It only took the stock until the end of February to accomplish that goal. And that was before Novavax's exciting announcement, made after the market closed on Wednesday. Investors had eagerly awaited the biotech's update of results from its phase 1 study of experimental flu vaccine NanoFlu. The wait is over. Based on those results, Novavax stock soared in after-hours trading Wednesday evening. Is now the time to buy the hot biotech stock -- or is it smarter to wait? Image source: Getty Images. Fantastic news Novavax's management team was on cloud nine back in August 2017 when the company announced pre-clinical results for NanoFlu. The biotech quickly advanced the nanoparticle-based flu vaccine into clinical testing. Now the highlights from the results for the phase 1 portion of the clinical study are available. If I could only use one word to describe those top-line results, … [Read more...] about Buy Novavax Stock Now — or Wait?
There's no such thing as a riskless investment, especially when it comes to stocks. You can, however, mitigate the risks associated by opting for "low risk" stocks, which, in my opinion, typically belong to companies with strong competitive advantages, rock-solid balance sheets, and a prudent management team that can steer the company just as well through downs as ups to generate strong shareholder returns year after year. Such companies also usually pay steady dividends, further adding to their appeal. Think 3M (NYSE: MMM), Stanley Black & Decker (NYSE: SWK), and Brookfield Infrastructure Partners (NYSE: BIP) -- all three are great stocks that would fit any risk-averse investor's portfolio. A brand powerhouse If you've ever used hand and power tools to repair your home or car, you've probably heard of Stanley Black & Decker. What started as a bolts and hinges company in 1843 is among the world's leading diversified industrial machinery manufacturers today and has built a … [Read more...] about 3 Great Stocks for Low-Risk Investors
When Mylan N.V. (NASDAQ: MYL) reported its third-quarter 2017 results in November, the drugmaker had good news and bad news. The bad news was that the company's revenue and adjusted earnings fell. The good news, though, was that Mylan executives boosted its full-year 2017 guidance. Mylan announced its fourth-quarter and full-year 2017 results after the market closed on Wednesday. Did the company meet its expectations? It did. And while there were still some weak spots, the drugmaker's performance improved from the third quarter. Here are the highlights from Mylan's fourth-quarter update. Image source: Getty Images. Mylan results: The raw numbers Metric Q4 2017 Q4 2016 Year-Over-Year Change Revenue $3.24 billion $3.27 billion (1%) Net income from continuing operations $244.3 million $417.5 million (41%) Adjusted earnings per share (EPS) $1.43 $1.57 (9%) Data source: Mylan. What happened with Mylan this quarter? If it were not for … [Read more...] about Mylan N.V. Sees Signs of Improvement in the 4th Quarter
U.S. oil and gas driller ConocoPhillips (NYSE: COP) had been lagging big oil companies like ExxonMobil (NYSE: XOM) throughout the oil price downturn, a victim of having spun off its refining and marketing arm as Phillips 66 (NYSE: PSX) in 2012. All of that -- well, some of that -- changed in 2017 as rising oil prices boosted ConocoPhillips' stock price. It ended up not only handily outperforming many of its peers, but also outperforming ExxonMobil for the year. But a single good year doesn't make a trend. Let's see what's in store for Conoco this year to try to determine if it really is a buy. Oil and gas industry player ConocoPhillips outperformed in 2017. Can it repeat its success this year? Image source: Getty Images. Keep on flowing Conoco's fourth-quarter 2017 earnings release, which came on February 1, just before the big market correction, showed big year-over-year improvement. The company had a banner 2017, achieving full-year production of 1.3 million barrel of oil … [Read more...] about Is ConocoPhillips a Buy?